Literature DB >> 6630761

Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients.

G N Kay, V J Plumb, J G Arciniegas, R W Henthorn, A L Waldo.   

Abstract

The clinical setting, precipitating factors, electrocardiographic features and response to treatment of 32 patients with torsade de pointes were reviewed. Thirty-one patients had underlying cardiac disease and 30 patients had a previous underlying cardiac arrhythmia. Antiarrhythmic medications, often in association with electrolyte abnormalities (such as hypokalemia and hypomagnesemia) were the most common precipitating factors. In 22 of 26 patients, the serum drug levels of the antiarrhythmic agents were found to be within the therapeutic range. However, before the administration of agents known to prolong the QT interval, 20 of the 32 patients had, either alone or in combination, baseline prolongation of the QT interval, hypokalemia or hypomagnesemia. All patients had QTc interval prolongation (mean 0.59 second) immediately before the development of torsade de pointes. Marked lability of T wave morphology was frequently noted. Cardiac pacing was the only consistently effective mode of therapy. A characteristic long-short ventricular cycle length as the initiating sequence was found in 41 of 44 episodes of torsade de pointes. Reported data support the high frequency of this electrocardiographic feature of torsade de pointes in which its onset could be analyzed. It is suggested that this electrocardiographic characteristic will aid in both establishing the diagnosis of torsade de pointes and distinguishing it from other polymorphic forms of ventricular tachycardia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6630761     DOI: 10.1016/s0735-1097(83)80226-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  68 in total

1.  [Transmural ERP-dispersion from epi-, mid-and endomyocardium in healthy and hypertrophied dog myocardium].

Authors:  J Lü; Z Lu; F Voss; W Schöls
Journal:  J Tongji Med Univ       Date:  2001

2.  Torsades de Pointes.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-08

3.  The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes.

Authors:  Elijah R Behr; Craig January; Eric Schulze-Bahr; Andrew A Grace; Stefan Kääb; Monica Fiszman; Shaniece Gathers; Shaavhrée Buckman; Ashraf Youssef; Munir Pirmohamed; Dan Roden
Journal:  Eur Heart J       Date:  2012-07-02       Impact factor: 29.983

Review 4.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 5.  A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs?

Authors:  F A Fish; D M Roden
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

Review 6.  Electrophysiologic mechanisms involved in the development of torsades de pointes.

Authors:  S G Priori; C Napolitano; P J Schwartz
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

7.  Modelling and imaging cardiac repolarization abnormalities.

Authors:  Y Rudy
Journal:  J Intern Med       Date:  2006-01       Impact factor: 8.989

8.  Vulnerable window for conduction block in a one-dimensional cable of cardiac cells, 2: multiple extrasystoles.

Authors:  Zhilin Qu; Alan Garfinkel; James N Weiss
Journal:  Biophys J       Date:  2006-05-05       Impact factor: 4.033

9.  Effectiveness of ibutilide in cardioversion of persistent atrial fibrillation in patients with dual chamber stimulation.

Authors:  Massimo Santini; Carlo Pignalberi; Renato Ricci; Leonardo Calò; Luca Santini
Journal:  J Interv Card Electrophysiol       Date:  2003-08       Impact factor: 1.900

Review 10.  Genetics of acquired long QT syndrome.

Authors:  Dan M Roden; Prakash C Viswanathan
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.